Literature DB >> 7580295

Pulmonary hypertension in rats. 2. Role of interleukin-6.

M Miyata1, F Sakuma, A Yoshimura, H Ishikawa, T Nishimaki, R Kasukawa.   

Abstract

We administered human interleukin (IL)-6 to rats to examine whether it is implicated in the development of pulmonary hypertension (PH). The rats injected with IL-6 developed PH as determined by the weight ratio of the right ventricle to the left ventricle+septum. This ratio decreased with the appearance of IgG anti-human IL-6 antibody. Histologically we observed in the lungs, luminal occlusion of small muscular arteries, capillaries filled with fibrin thrombi, and localized hemorrhage. IL-6 increased the number of platelets, and the number of platelets correlated with the extent of PH. Thus, it seems likely that (IL-6) is involved in the formation of PH in this model.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7580295     DOI: 10.1159/000237166

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  24 in total

Review 1.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension.

Authors:  Yuichi Tamura; Carole Phan; Ly Tu; Morane Le Hiress; Raphaël Thuillet; Etienne-Marie Jutant; Elie Fadel; Laurent Savale; Alice Huertas; Marc Humbert; Christophe Guignabert
Journal:  J Clin Invest       Date:  2018-04-09       Impact factor: 14.808

3.  Human herpesvirus-8 infection of primary pulmonary microvascular endothelial cells.

Authors:  Todd M Bull; Christina A Meadows; Christopher D Coldren; Mark Moore; Sylk M Sotto-Santiago; Serge P Nana-Sinkam; Thomas B Campbell; Mark W Geraci
Journal:  Am J Respir Cell Mol Biol       Date:  2008-06-27       Impact factor: 6.914

Review 4.  Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch; Christophe Guignabert; Marc Humbert; Mark R Nicolls
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

5.  Inflammatory Response of Pulmonary Artery Smooth Muscle Cells Exposed to Oxidative and Biophysical Stress.

Authors:  Joanna Costa; Yan Zhu; Timothy Cox; Paul Fawcett; Thomas Shaffer; Deepthi Alapati
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

6.  Effects of olmesartan, an AT1 receptor antagonist, on hypoxia-induced activation of ERK1/2 and pro-inflammatory signals in the mouse lung.

Authors:  Yoshiyuki Tanabe; Yuki Morikawa; Takao Kato; Satoshi Kanai; Taichi Watakabe; Ami Nishijima; Hijiri Iwata; Kaori Isobe; Mayumi Ishizaki; Koichi Nakayama
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-07       Impact factor: 3.000

7.  Interleukin-6 overexpression induces pulmonary hypertension.

Authors:  M Kathryn Steiner; Olga L Syrkina; Narasaish Kolliputi; Eugene J Mark; Charles A Hales; Aaron B Waxman
Journal:  Circ Res       Date:  2008-12-12       Impact factor: 17.367

8.  The effect of fetal stabilization using morphine hydrochloride on neonatal rats.

Authors:  Toru Uesugi; Kouji Masumoto; Kouji Nagata; Tomoaki Taguchi; Sachiyo Suita
Journal:  Pediatr Surg Int       Date:  2007-10       Impact factor: 1.827

9.  Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension.

Authors:  Kurt W Prins; Stephen L Archer; Marc Pritzker; Lauren Rose; E Kenneth Weir; Alok Sharma; Thenappan Thenappan
Journal:  J Heart Lung Transplant       Date:  2017-09-01       Impact factor: 10.247

10.  Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease.

Authors:  Xiaomei Niu; Mehdi Nouraie; Andrew Campbell; Sohail Rana; Caterina P Minniti; Craig Sable; Deepika Darbari; Niti Dham; N Scott Reading; Josef T Prchal; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro; Victor R Gordeuk
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.